The updated vaccines are a key part of the Biden administration’s plan to control COVID-19 ahead of an expected new wave of cases in winter when more people will spend time indoors. The government has earmarked billions of dollars to secure supplies of both inoculations, which it said could be available as soon as early September.
The regulatory process to meet that timeframe, however, is a bit of a high-wire act. Neither Pfizer nor Moderna have clinical trial results on the versions of the shots they have submitted.
